Clinical trialNCT02118727CompletedPhase 2Interventional

Therapy in Amyotrophic Lateral Sclerosis (TAME)

SponsorUniversity of Kansas Medical CenterEnrollment89Amyotrophic Lateral SclerosisFrontal Temporal Dementia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to determine if memantine at up to 20 mg twice a day when used in conjunction with riluzole, can slow down the disease progression of patients with ALS including potentially improving their neuropsychiatric changes, as well as determine if serum biomarkers can be used both as a diagnostic and a prognostic marker in patients with ALS. Funding Source: FDA - Orphan Products Development (OPD)

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Richard J Barohn, MD
University of Missouri Health Care
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

13 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Phoenix Neurological Associates
Phoenix, Arizona, United States
Uc Irvine
Irvine, California, United States
University of Florida
Jacksonville, Florida, United States
University of Kansas Medical Center
Kansas City, Kansas, United States
University of Kansas School of Medicine - Wichita
Wichita, Kansas, United States
University of Kentucky
Lexington, Kentucky, United States
University of Missouri
Columbia, Missouri, United States
Coxhealth
Springfield, Missouri, United States
Providence Health Sciences
Portland, Oregon, United States
Penn State Hershey Medical Center
Hershey, Pennsylvania, United States
Austin Neuromuscular Center
Austin, Texas, United States
Nerve & Muscle Center of Texas
Houston, Texas, United States
University of Washington
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Memantine →Placebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 7 Nov 2018
Primary completion: 22 Jul 2021
Completion: 22 Jul 2021
Last update posted: 29 Nov 2022
Registered enrollment: 89
Registry id: NCT02118727

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.